Company Directory / Biotechnology
Public · FRA:TG4For profitBiotechnologyLeuven, Belgium
Oxurion
Oxurion is a biotech drug development company focused on developing therapies for retinal disorders, now focusing on diabetic eye diseases.
- Founded
- 1991 35 years ago
- Staff
- 51-100 34 on LinkedIn
- Followers
- 8k on LinkedIn
- Funding
- $194M as listed, USD
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment… Read all
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Set against six million companies
Size
51-100 people: larger than 75% of companies with a size listed. 34 people list it on LinkedIn.
Age
35 years old.
Reach
Website ranked #8,360,538 in the world for traffic, about 555 visits a month. 7,977 followers on LinkedIn.
What it does
BiotechnologyLife ScienceMedical
Funding, as listed
$194M raised in total
- Rounds12
- LatestPost ipo debt, Apr 2024
- Latest amountUSD 483,351
- Investors4, 2 leading
What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.
Every detail we hold
Everything the source datasets list about Oxurion, field by field. Contact details are held but never shown.
The company
- Name
- Oxurion
- Type
- For profit
- Status
- Public · FRA:TG4
- Founded
- 1991
- Industry
- Biotechnology
- Categories
- Biotechnology, Life Science, Medical
Where
- City
- Leuven
- Country
- Belgium
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 51-100
- People on LinkedIn
- 34
- LinkedIn followers
- 7,977
- Web traffic rank
- #8,360,538
- Monthly web visits
- 555
Funding, as listed
- Total
- $194,151,447 USD
- Rounds
- 12
- Latest round
- Post ipo debt
- Latest round date
- Apr 2024
- Latest amount
- 483,351 USD
- Investors
- 4
- Lead investors
- 2
- Stock listing
- FRA:TG4
- Listing status
- public
About this record
- Sources
- Crunchbase, LinkedIn
- Last imported
- Sept 2026
Companies like it
Biotechnology in Belgium.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 36,920 companies in Belgium and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.